Monopar Therapeutics Files 8-K: Acquisition, Debt, and Equity Sales

Ticker: MNPR · Form: 8-K · Filed: 2024-10-24T00:00:00.000Z

Sentiment: neutral

Topics: acquisition, debt, equity-sale, material-agreement

TL;DR

Monopar Therapeutics filed an 8-K detailing an acquisition, new debt, and equity sales. Big moves happening!

AI Summary

On October 23, 2024, Monopar Therapeutics Inc. entered into a material definitive agreement related to the completion of an acquisition. The company also disclosed the creation of a direct financial obligation and reported unregistered sales of equity securities. This filing indicates significant corporate activity and potential financial restructuring.

Why It Matters

This 8-K filing signals substantial corporate actions for Monopar Therapeutics, including an acquisition, new financial obligations, and equity sales, which could impact its financial standing and future operations.

Risk Assessment

Risk Level: medium — The filing indicates significant corporate events including an acquisition, new financial obligations, and equity sales, which introduce financial and operational risks.

Key Players & Entities

FAQ

What specific material definitive agreement did Monopar Therapeutics enter into?

The filing indicates the entry into a material definitive agreement but does not specify its details in the provided text.

What is the nature of the direct financial obligation created by Monopar Therapeutics?

The filing states the creation of a direct financial obligation but does not provide specific details about its terms or amount.

What were the circumstances of the unregistered sales of equity securities?

The filing reports unregistered sales of equity securities but does not provide details on the number of shares, price, or purchasers.

What is the significance of the 'Completion of Acquisition or Disposition of Assets' item?

This item suggests that Monopar Therapeutics has recently completed a transaction involving the acquisition or sale of assets, a key corporate event.

What is the purpose of the 'Regulation FD Disclosure' item in this filing?

This item indicates that Monopar Therapeutics is making public disclosures to ensure fair and non-discriminatory dissemination of material information to investors.

From the Filing

0001437749-24-031957.txt : 20241024 0001437749-24-031957.hdr.sgml : 20241024 20241024070040 ACCESSION NUMBER: 0001437749-24-031957 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 18 CONFORMED PERIOD OF REPORT: 20241023 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Completion of Acquisition or Disposition of Assets ITEM INFORMATION: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant ITEM INFORMATION: Unregistered Sales of Equity Securities ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20241024 DATE AS OF CHANGE: 20241024 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Monopar Therapeutics CENTRAL INDEX KEY: 0001645469 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 320463781 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39070 FILM NUMBER: 241390681 BUSINESS ADDRESS: STREET 1: 1000 SKOKIE BLVD SUITE 350 CITY: WILMETTE STATE: IL ZIP: 60091 BUSINESS PHONE: 8473880349 MAIL ADDRESS: STREET 1: 1000 SKOKIE BLVD SUITE 350 CITY: WILMETTE STATE: IL ZIP: 60091 8-K 1 mnpr20241021_8k.htm FORM 8-K mnpr20241021_8k.htm false 0001645469 0001645469 2024-10-23 2024-10-23     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM 8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934   Date of Report (Date of earliest event reported): October 23, 2024   MONOPAR THERAPEUTICS INC. (Exact name of registrant as specified in its charter)   Delaware   001-39070   32-0463781 (State or other jurisdiction of incorporation)   (Commission File Number)   (I.R.S. Employer Identification No.)   1000 Skokie Blvd. , Suite 350 , Wilmette , IL   60091 (Address of principal executive offices)   (Zip Code)   ( 847 ) 388-0349 Registrant’s telephone number, including area code   N/A (Former name or former address, if changed since last report)   Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, $0.001 par value   MNPR   The Nasdaq Stock Market LLC (Nasdaq Capital Market)   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ☐  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).   Emerging growth company ☒   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒         Item 1.01                    Entry into a Material Definitive Agreement.   On October 23, 2024, Monopar Therapeutics Inc. (the “Company” or “Monopar”) executed a License Ag

View on Read The Filing